Cardiovascular disease determinants in chronic renal failure: Clinical approach and treatment

Nephrology Dialysis Transplantation

Volumn 16, Issue 3, 2001, Pages 459-468

  Locatelli, Francesco ^a   Bommer, Jürgen ^b   London, Gérard Michel ^c   Martín Malo, Alejandro ^d   Wanner, Christoph ^e   Yaqoob, Mohammed ^f   Zoccali, Carmine ^g  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Hopital Manhes   (France)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g Reggio Cal Hospital   (Italy)

Author keywords

Anaemia; Cardiovascular disease; Convective treatments; Dyslipidaemia; Hyperparathyroidism; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; TRIACYLGLYCEROL;

AMYLOIDOSIS; ANEMIA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG TOLERANCE; DRUG USE; DYSLIPIDEMIA; FERRITIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPARATHYROIDISM; HYPERTENSION; INFECTION; INFLAMMATION; IRON THERAPY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035098313     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.3.459     Document Type: Article

References (60)

1. Report on management of renal failure in Europe, XXV, 1994: End-stage renal disease and dialysis report
2. Chronic renal failure-a vasculopathic state
3. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
4. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis
5. Cardiac function and hematocrit level
6. Hyperphosphataemia-a silent killer of patients with renal failure?
7. Whither goest Kt/V?
8. Hypertension in the hemodialysis population: Any relation to one-year survival?
9. Cardiac disease in chronic uremia: Pathogenesis
10. Outcome and risk factors for left ventricular disorders in chronic uraemia
11. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h-ambulatory BP monitoring in haemodialysis patients
12. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
13. Myocyte/capillary mismatch in the heart of uremic patients
14. Hypertension as a possible complication of recombinant human erythropoietin therapy
15. Cardiovascular consequences of renal anaemia and erythropoietin therapy
16. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
17. Normalization of haemoglobin: Why not?
18. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
19. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
20. Optimal haemoglobin during treatment with recombinant human erythropoietin
21. Iron therapy and cardiovascular disease
22. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients
23. Effect of parathyroidectomy on left ventricular function in haemodialysis patients
24. Long-term effects of parathyroidectomy on cardiac and autonomic nervous system functions in haemodialysis patients
25. Parathyroid hormone and myocardial performance in dialysis patients
26. Calcification of the aortic valve in the dialysed patient
27. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
28. Evolutive aortic stenosis in haemodialysis patients: Analysis of risk factors
29. Arterial stiffening and vascular calcifications in end-stage renal disease
30. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients: A national study
31. Hyperlipidemia in patients with chronic renal disease
32. Serum lipids predict cardiac death in diabetic patients on maintenance haemodialysis: Results of a prospective study
33. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
34. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
35. Atherosclerosis-an inflammatory disease
36. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
37. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
38. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
39. Reversal of hyperhomocysteinaemia in CRF-is folic acid or folinic acid the answer?
40. Asymmetric dimethylarginine plasma concentrations differ in patients with ESRD: Relationship to treatment method and atherosclerotic disease
41. Effect of the dialysis membrane on mortality of chronic hemodialysis patients
42. Relationship of dialysis membrane and cause-specific mortality
43. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients
44. The effects of the dialysis membrane on cytokine release
45. Morbidity and mortality in ESRD patients on convective or on diffusive extracorporeal treatment
46. 2-microglobulin amyloidosis in haemodialysis: A prospective post-mortem study
47. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters
48. C-reactive protein and coronary artery disease-what is the link?
49. Cytokines and bioincompatibility
50. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis
51. IL-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients
52. Immunologic function and survival in haemodialysis patients
53. The Hemodialysis (HEMO) study: Rationale for selection of interventions
54. The effect of membrane permeability on ESRD: Design of a prospective randomised trial
55. Effects of haemodialysis and hypertonic hemodiafiltration on cardiac function compared
56. Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study
57. Membrane biocompatibility: Effects on cardiovascular stability in patients on hemodiafiltration
58. Tolerance of hemodialysis: A randomized, prospective trial of high-flux versus conventional high-efficiency hemodialysis